Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Par Responds To Process Patents: FineTech Acquisition Valued At $109 Mil.

Executive Summary

Par's acquisition of ISP's FineTech chemical business reflects the generic drug company's desire to gain greater control over all aspects of the manufacturing process in the current environment of patent disputes

You may also be interested in...



Prilosec Generics Stability Review By FDA To Be Completed By Mid-November

FDA expects to complete its review of data submitted by AstraZeneca regarding the long-term stability of omeprazole generics in a month.

Tambocor Dispute, FTC Report May Keep Generic Drugs On Congress' Agenda

A dispute between Par and Barr over generic exclusivity for flecainide reflects the continued complexities in the Waxman/Hatch process that could drive Congressional action over the next 18 months.

Par Aims To Add Branded Products After Merck KGaA Divests Equity Stake

Par is looking to add branded products to its portfolio as it seeks to join the top-tier independent generic drug companies after Merck KGaA divests its controlling interest in the firm.

Related Content

UsernamePublicRestriction

Register

PS039186

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel